<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03096613</url>
  </required_header>
  <id_info>
    <org_study_id>2016-798</org_study_id>
    <nct_id>NCT03096613</nct_id>
  </id_info>
  <brief_title>Thyroid Hormone Replacement for Subclinical Hypothyroidism and Chronic Heart Failure (ThyroHeart-CHF)</brief_title>
  <official_title>Efficacy and Safety of Levothyroxine (L-T4) Replacement on Exercise Capability in Chronic Systolic Heart Failure Patients With Subclinical Hypothyroidism: A 24-week, Multi-center, Open Label, Randomized, Parallel Group Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Luhe Teaching Hospital of the Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Second Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on accumulating evidence showing that hypothyroid status is associated with poor&#xD;
      prognosis among heart failure (HF) patients, the study is designed to evaluate whether&#xD;
      replacement treatment with levothyroxine could have beneficial effects on patients with HF&#xD;
      and subclinical hypothyroidism. The study is a prospective, randomized, parallel-group trial&#xD;
      to assess the efficacy and safety of levothyroxine replacement on evidence-based HF standard&#xD;
      therapy in stable chronic heart failure patients with subclinical hypothyroidism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this trial is to determine whether the 24-week L-T4 replacement&#xD;
      therapy, as an adjunct to standard treatment, would improve exercise capability in chronic&#xD;
      systolic heart failure patients with subclinical hypothyroidism compared to the standard&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 18, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distance difference of Six-minute Walk Test (6MWT) between week 24 and baseline</measure>
    <time_frame>Within 6 months of patient enrolled</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference of the plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) level between week 24 and baseline</measure>
    <time_frame>Within 6 months of patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NYHA classification between week 24 and baseline.</measure>
    <time_frame>Within 6 months of patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of cardiovascular death or heart failure re-hospitalization during the 24 weeks treatment</measure>
    <time_frame>Within 6 months of patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of cardiovascular death, re-hospitalization for cardiovascular disease, severe arrhythmia, and stroke during the 24 weeks treatment</measure>
    <time_frame>Within 6 months of patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of echocardiographic and cardiac magnetic resonance imaging measures between week 24 and baseline</measure>
    <time_frame>Within 6 months of patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of MLHFQ between week 24 and baseline</measure>
    <time_frame>Within 6 months of patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of serum lipid profiles between week 24 and baseline</measure>
    <time_frame>Within 6 months of patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Within 6 months of patient enrolled</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Heart Failure</condition>
  <condition>Subclinical Hypothyroidism</condition>
  <arm_group>
    <arm_group_label>Levothyroxine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients allocated to levothyroxine group receive levothyroxine with a starting dose of 12.5ug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patients in this group receive standard therapy in consistent with the local clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine</intervention_name>
    <description>Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.</description>
    <arm_group_label>Levothyroxine group</arm_group_label>
    <other_name>Euthyrox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years or older, male or female.&#xD;
&#xD;
          -  Systolic heart failure with New York Heart Association (NYHA) class II-III.&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) less than 40% by echocardiography during&#xD;
             screening and randomization.&#xD;
&#xD;
          -  SCH (TSH: upper limits of normal (ULN) -10mIU/L, and FT4 level within reference&#xD;
             range).&#xD;
&#xD;
          -  Having received standard HF therapy for at least 2 weeks, having reached target dose&#xD;
             or max tolerable dose.&#xD;
&#xD;
          -  Provided informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute heart failure or acute exacerbation of chronic heart failure within the past 2&#xD;
             weeks.&#xD;
&#xD;
          -  Scheduled cardiac resynchronization therapy or heart transplantation.&#xD;
&#xD;
          -  History of malignant tumor or life expectancy under 12 months.&#xD;
&#xD;
          -  Already on medications that may affect thyroid function (L-T4, carbimazole,&#xD;
             propylthiouracil, amiodarone, lithium).&#xD;
&#xD;
          -  Pregnancy and lactation period.&#xD;
&#xD;
          -  Participation in another clinical trial within the past 30 days.&#xD;
&#xD;
          -  Contraindication or intolerance to evidence-based therapy for CHF, such as&#xD;
             beta-blocker, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.&#xD;
&#xD;
          -  Known hypersensitivity to the trial treatment(s) or diluents (when applicable),&#xD;
             including placebo or other comparator drug(s).&#xD;
&#xD;
          -  Untreated adrenal insufficiency.&#xD;
&#xD;
          -  Untreated pituitary insufficiency.&#xD;
&#xD;
          -  Untreated thyrotoxicosis.&#xD;
&#xD;
          -  Treatment with levothyroxine must not be initiated in patients with acute myocardial&#xD;
             infarction, acute myocarditis, or acute pancarditis.&#xD;
&#xD;
          -  Severe renal dysfunction (eGFRâ‰¤30 ml/min/1.73m2).&#xD;
&#xD;
          -  Significant hepatic impairment (Serum GPT &gt; 120 U/L).&#xD;
&#xD;
          -  Any disorder which, in the opinion of the investigator, might jeopardise subject's&#xD;
             safety or compliance with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Da Tang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuan Zhang, MD</last_name>
    <phone>00861088396173</phone>
    <email>katiechang@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kuo Zhang, MD</last_name>
    <phone>008618813019602</phone>
    <email>kzhang23@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences, Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenyao Wang, MD</last_name>
      <phone>00861088396173</phone>
      <email>wwypumc@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 25, 2017</study_first_submitted>
  <study_first_submitted_qc>March 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2017</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Yi-Da Tang</investigator_full_name>
    <investigator_title>Professor, chief physician</investigator_title>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>Subclinical Hypothyroidism</keyword>
  <keyword>levothyroxine</keyword>
  <keyword>6-minute walk test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

